Downloads
Abstract
Mature B cell lymphoma (B - NHL) is a highly aggressive and fast - growing human disease in children.
The outcome of childhood B - NHL treatment has improved steadily through the use of intensive multi - agent chemotherapy regimens. This study aims to reveal the outcome of treatment according to LMB 96
protocol in Vietnam National Children’s Hospital (VNCH).
Objective and methods: A descriptive study was carried out in all B - NHL patients under 16 years old
that start their treatment in VN CH since 01 January 2015 and end before 30 June 2021, excluding patients
can’t follow up.
Results: Eighty - four patients were diagnosed with B - NHL, who underwent chemotherapy by the
LMB96 protocol and followed up in 6 years. Twenty - three patients (27.4%) died. The main cause of death
was severe sepsis related to grade IV neutropenia in 11.9% of the patients. The 6 years OS and EFS were
69.6% and 63.9%, respectively, for the whole groups of patients. The 6 years OS and EFS were 77.2% and
76.7% at stage III; 46.4% and 35.7% at stage 4, lower than at stage Iand II (p = 0). The 6 years OS and
EFS in the group with LDH ≥ 1000 UI/ml were 58.2% and 52.6%, worse than in the group with LDH < 1000
UI/ml (p ≤ 0,05). OS and EFS in the non - bone marrow involvement group were much lower than the bone
marrow involvement patients (p ≤ 0,05). Tumor lysis syndrome was seen in 10.7% of the patients before
starting chemotherapy and 11.9% of those after the beginning of treatment, mostly occurs in patients with
LDH ≥ 1000 UI/ml, Burkitt lymphoma, stage 3 and 4.
Conclusion: The outcome of treatment mature B cell lymphoma in VNCH according to LMB 96 protocol
was similar to other results in developing countries but lower than those in developed countries.Supportive
care needs to improve to increase the survival rate.
References
Worch J, Rohde M, Burkhardt B. Mature B -
cell lymphoma and leukemia in children and
adolescents - review of standard chemotherapy
regimen and perspectives. Pediatr Hematol
Oncol. 2013;30(6):465-483.
Cunha KCCMS, Oliveira MCLA, Gomes ACS,
de Castro LPF, Viana MB. Clinical course and
prognostic factors of children with Burkitt’s
lymphoma in a developing country: the
experience of a single centre in Brazil. Rev Bras
Hematol E Hemoter. 2012;34(5):361-366.
Gaytan - Morales F, Alejo - Gonzalez F, Reyes
- Lopez A, et al. Pediatric mature B - cell NHL,
early referral and supportive care problems
in a developing country. Hematol Amst Neth.
;24(1):79-83.
Patte C, Auperin A, Michon J, et al. The
Société Française d’Oncologie Pédiatrique
LMB89 protocol: highly effective multiagent
chemotherapy tailored to the tumor burden and
initial response in 561 unselected children with
B - cell lymphomas and L3 leukemia. Blood.
;97(11):3370-3379.
Gerrard M, Cairo MS, Weston C, et al.
Excellent survival following two courses
of COPAD chemotherapy in children and
adolescents with resected localized B - cell
non - Hodgkin’s lymphoma: results of the FAB/
LMB 96 international study. Br J Haematol.
;141(6):840-847.
Cairo MS, Gerrard M, Sposto R, et al. Results
of a randomized international study of high -
risk central nervous system B non-Hodgkin
lymphoma and B acute lymphoblastic
leukemia in children and adolescents. Blood.
;109(7):2736-2743.
Tsurusawa M, Mori T, Kikuchi A, et al.
Improved treatment results of children with B -
cell non - Hodgkin lymphoma: a report from the
Japanese Pediatric Leukemia/Lymphoma Study
Group B - NHL03 study. Pediatr Blood Cancer.
;61(7):1215-1221.
Rigaud C, Auperin A, Jourdain A, et al. Outcome
of relapse in children and adolescents with B -
cell non - Hodgkin lymphoma and mature acute
leukemia: A report from the French LMB study.
Pediatr Blood Cancer. 2019;66(9):e27873.
Eldar AH, Futerman B, Abrahami G, et al. Burkitt
lymphoma in children: the Israeli experience. J
Pediatr Hematol Oncol. 2009;31(6):428-436.
Reiter A, Klapper W. Recent advances in the
understanding and management of diffuse large
B - cell lymphoma in children. Br J Haematol.
;142(3):329-347.
Perkins SL. Work - up and diagnosis of pediatric
non - Hodgkin’s lymphomas. Pediatr Dev Pathol
Off J Soc Pediatr Pathol Paediatr Pathol Soc.
;3(4):374-390.
Patte C, Auperin A, Gerrard M, et al. Results of
the randomized international FAB/LMB96 trial for
intermediate risk B - cell non - Hodgkin lymphoma
in children and adolescents: it is possible to reduce
treatment for the early responding patients. Blood.
;109(7):2773-2780.
Mukhtar F, Boffetta P, Risch HA, et al. Survival
predictors of Burkitt’s lymphoma in children, adults
and elderly in the United States during 2000 - 2013.
Int J Cancer. 2017;140(7):1494-1502.
Cairo MS, Sposto R, Gerrard M, et
al. Advanced stage, increased lactate
dehydrogenase, and primary site, but not
adolescent age (≥ 15 years), are associated
with an increased risk of treatment failure in
children and adolescents with mature B - cell
non - Hodgkin’s lymphoma: results of the
FAB LMB 96 study. J Clin Oncol Off J Am
Soc Clin Oncol. 2012;30(4):387-393.
Abdel Rahman H, Moussa E, Sedki M. Pediatric
mature B - cell non Hodgkin lymphoma
treatment with LMB - 96 protocol. The Children
Cancer Hospital Egypt experience. Int J Cancer
Ther Oncol. 2015;3:3215.
Pession A, Masetti R, Gaidano G, et al. Risk
evaluation, prophylaxis, and treatment of tumor
lysis syndrome: consensus of an Italian expert
panel. Adv Ther. 2011;28(8):684-697.
Cairo MS, Coiffier B, Reiter A, Younes A, TLS
Expert Panel. Recommendations for the evaluation
of risk and prophylaxis of tumour lysis syndrome
(TLS) in adults and children with malignant
diseases: an expert TLS panel consensus. Br J
Haematol. 2010;149(4):578-586.
| Published | 06-12-2021 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 74 (2021) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.2021.74.14 | |
| Keywords | U lympho tế bào B trưởng thành, Bệnh viện Nhi trung ương, kết quả điều trị Mature B cell lymphoma, outcome, Vietnam National Children’s Hospital. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Journal of Clinical Medicine Hue Central Hospital